Alliance Pharmaceutical Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alliance Pharmaceutical Corp.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
The SMC has given the all clear to funding for Lilly’s Verzenios for breast cancer, Richter’s Reagila for schizophrenia, and MSD’s Keytruda for melanoma. However, it rejected Alliance’s Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.
Sanofi and Regeneron teamed up in a second major deal, focused on immuno-oncology; after an unsuccessful try at Mylan, Teva bought Allergan's generics business. Between June and July, biopharma companies raised over $10 billion, and device firms more than $1 billion.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced June-July 2015.
- In Vitro Diagnostics